Aura Renew Acq Regulatory News (ARA)

11 Oct 2006 13:51

Ardana PLC11 October 2006 Ardana plc Annual General Meeting Edinburgh, UK, 11 October 2006 - Ardana plc (LSE: ARA.L) confirms that allresolutions put to the Annual General Meeting on 11 October 2006 were dulypassed. Enquiries: Ardana plc+44 (0)131 226 8558Dr Maureen Lindsay, Chief Executive OfficerGraham Lee, Chief Financial Officer Financial Dynamics+44 (0)20 7831 3113Julia PhillipsJohn Gilbert About Ardana Ardana plc is a pharmaceutical company focused on the discovery, development andmarketing of innovative products to improve human reproductive health, a $25.5billion market. Since its foundation, Ardana has maintained a broad and balanced portfolio tomanage risk and actively pursues product and technology in-licensing andout-licensing to maintain a robust pipeline. Ardana's lead products are summarised below: • Emselex(R), a treatment for overactive bladder for which Ardana has sole and exclusive promotion rights in the UK and will be launched in collaboration with Novartis Pharmaceuticals UK Limited; • StriantSR, a testosterone replacement therapy for which Ardana has marketing rights in Europe, has been launched by Ardana through its own sales force in the UK and partners in various European countries, as a treatment for men with confirmed hypogonadism; • Teverelix LA, in development for three initial indications: prostate cancer and benign prostatic hyperplasia (both indications are at the phase II stage), and endometriosis (currently in phase I); • Testosterone Cream, a transdermal testosterone delivery system in phase II for the treatment of male hypogonadism; • Invicorp(R), an injectable combination drug treatment for erectile dysfunction, already approved in Denmark and for which Ardana has marketing and manufacturing rights in Europe. Launch is expected in H2 2006; In addition, Ardana has a strong portfolio of follow-on products in development. For further information please see www.ardana.co.uk This information is provided by RNS The company news service from the London Stock Exchange